
Madlen Marx

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8157851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reduction of CD11b ⁺ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD ₂ antibody ch14.18/CHO. Oncolmmunology, 2020, 9, 1836768.	4.6	6
2	GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. Journal of Neuro-Oncology, 2020, 147, 577-585.	2.9	18
3	Low CD4âº/CD25âº/CD127â» regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2. Oncolmmunology, 2019, 8, 1661194.	4.6	14
4	Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice. PLoS ONE, 2018, 13, e0207320.	2.5	5
5	Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers, 2018, 10, 387.	3.7	13
6	PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD ₂ antibody ch14.18/CHO. Oncolmmunology, 2017, 6, e1343775.	4.6	53
7	Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. Oncolmmunology, 2016, 5, e1235108.	4.6	39
8	Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs, 2016, 8, 604-616.	5.2	43
9	Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody. PLoS ONE, 2014, 9, e107692.	2.5	25